Exploring the relation between the EQ-5D-5L pain/discomfort and pain and itching in a sample of burn patients by Spronk, I. (I.) et al.
RESEARCH Open Access
Exploring the relation between the EQ-5D-
5L pain/discomfort and pain and itching in
a sample of burn patients
I. Spronk1,2* , G. J. Bonsel1,3, S. Polinder1, M. E. van Baar1,2, M. F. Janssen4 and J. A. Haagsma1
Abstract
Background: The EQ-5D domain pain/discomfort (PD) uses one item to capture pain and other aspects of
discomfort, like itching. This study explored how pain, itching and the EQ-5D-5L PD domain relate to each other in
a sample of burn patients.
Methods: Adult burn patients completed the EQ-5D-5L and the Patient and Observer Scar Assessment Scale
(POSAS) 5–7 years after sustaining their injury. The POSAS includes a separate pain and an itching item. Spearman’s
correlation coefficient established the association between the EQ-5D-5L PD and the POSAS pain and itching item.
With multivariable regression analysis the linear association between the POSAS pain and itching item and EQ-5D-
5L PD domain was tested.
Results: Data from 245 patients were included. Mean EQ-5D-5L index value was 0.87 and 39.2% reported at least
slight problems on the EQ-5D-5L PD domain. Most patients gave corresponding answers on the EQ-5D-5L PD
domain and on the POSAS pain (73%) and itching (70%) item. Spearman correlation coefficients of the EQ-5D-5L
PD domain with the POSAS pain and itching were 0.468 (p < 0.001) and 0.473 (p < 0.001), respectively. Among
respondents with pain and without itching and respondents with itching and without pain, Spearman correlation
coefficients were 0.585 (p = 0.076) and 0.408 (p = 0.001), respectively. POSAS pain (unstandardized Beta = 0.14) and
POSAS itching (unstandardized Beta = 0.08) were significantly associated with EQ-5D-5L PD domain (p < 0.001).
Conclusions: Our findings indicate that, in a sample of burn patients, pain and itching are captured by the broader
EQ-5D-5L PD domain. The EQ-5D-5L PD domain can thus be used to assess pain and itching in relation to HRQL,
but the POSAS pain and itching items are more sensitive. The EQ-5D-5L is, however, no replacement of the POSAS
when the POSAS is used for its primary aim; assessment of scar quality.
Trial registration: Netherlands Trial Register (NTR6407).
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Background
Health-related quality of life (HRQL) assessment is in-
creasingly used to evaluate the consequences of a dis-
ease, condition or symptom, to assess the impact of
health interventions on these consequences, and to in-
vestigate the quality of care [1–3]. An extensively-used
instrument is the 5-dimensional EuroQol instrument
(EQ-5D). This short self-report instrument has been val-
idated for many diseases, and is available in many lan-
guages [4, 5]. The EQ-5D descriptive system consists of
five domains: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression, each of which can be
scored through a 3 or 5 level ordinal scale [6].
Pain, symptoms and other aspects of discomfort are
captured by the EQ-5D domain ‘pain/discomfort’ (EQ-
5D PD). However, unlike pain, other symptoms, condi-
tions, or complaints, such as itching, nausea, or feeling
breathless, are not explicitly defined. Still, these un-
defined aspects are assumed to be captured by this do-
main description. However, one study that explored the
extent to which psoriasis symptoms/problems were cap-
tured by the PD challenged this assumption [5]. Sup-
ported by literature evidence, in-depth interviews with
patients and clinicians, and psychometric analyses of
existing sources, the ‘bolt-on’ domain ‘skin irritation (e.g.
itching)’ was therefore added to the EQ-5D to create a
psoriasis-specific version of the EQ-5D.
We studied whether itching and pain are (sufficiently)
captured by the EQ-5D-5L PD domain, using EQ-5D-5L
data as well as separate pain and itching data from burn
patients, a specific patient group that experiences pain
and/or itching. Chronic pain and chronic itching in vari-
ous degrees of intensity and frequency are common
problems among burn patients [7–9]. Pain prevalence is
as high as 92% during hospitalization and decreases to-
wards 48% at 6 months, and 42% at 12 months following
burns [7]. After 4–7 years, still 26% of burn patients ex-
perience non-trivial, disturbing pain, with 12% reporting
high pain scores [10]. The prevalence rate for itching is
as high as 87% at 3 months post burn and drops to 67%
2 years following burns [8]. Itching remains a prevalent
problem (44–49%) in the long-term; 25% even reported
severe itching [10–12].
Our study aimed to explore how pain, itching and
the EQ-5D-5L PD domain relate to each other. First,
we investigated how pain and itching, as measured
separately through items of the Patient and Observer
Scar Assessment Scale (POSAS), relate to the re-
sponse to the EQ-5D-5L PD. Second, we investigated
the association, if any, between the POSAS pain and
itching items and the remaining EQ-5D-5L domains.
Third, we investigated if variability in pain and itch-
ing scores, measured with the POSAS, was captured
by the EQ-5D-5L PD domain.
Methods
Participants
The study had a cross-sectional design. Participants in-
cluded adult burn patients with a hospital stay of ≥1 day
or who had surgical treatment in one of the dedicated
Dutch burn centres (Red Cross Hospital Beverwijk, Mar-
tini Hospital Groningen, Maasstad Hospital Rotterdam)
between August 2011 and September 2012 [13]. This
sample was extended with patients with severe burns (>
20% total body surface area (TBSA) burned in patients
≤50 years old; > 10% TBSA burned in patients > 50 years;
or TBSA full thickness > 5% (based on the criteria of the
American Burn Association [14]) admitted between
January 2010 and March 2013. Those with pre-existing
cognitive impairments and with insufficient knowledge
of the Dutch language were excluded.
Between March 2017 and March 2018, eligible patients
were invited to participate via a postal invitation, includ-
ing an information letter, an informed consent form and
the survey. Patients who did not respond within 3 weeks
received a phone call (or a postal reminder when there
was no telephone number available) to discuss participa-
tion. The study was performed according to the princi-
ples of the Declaration of Helsinki, registered at the
Netherlands Trial Register (NTR6407), and approved by
the Ethics Committee (registration number NL59981).
Measures
Background information was derived from the Dutch
Burn Repository R3 [15]. Patient characteristics con-
sisted of age, gender and having chronic diseases. The
presence of any pre-existing chronic disease was defined
as having comorbidity; patients without a pre-existing
chronic disease were defined as not having comorbidity.
Injury characteristics, related to the entire burn history,
consisted of percentage total body surface area (%TBSA)
burned, % full-thickness burns, etiology, date of injury,
number of surgeries for burns, length of hospital stay for
burn injury, reconstructive surgery, artificial ventilation,
and time since burn. The survey included two existing
questionnaires: the EQ-5D-5L (Dutch language version)
and the patient part of the Patient and Observer Scar
Assessment Scale (POSAS) (Dutch language version), all
paper and pencil self-assessment.
The EQ-5D-5L includes items on five domains: mobil-
ity, self-care, usual activities, pain/discomfort, and anx-
iety/depression. Each domain has five ordered response
categories: no problems, slight problems, moderate
problems, severe problems and extreme problems. An
EQ-5D-5L index value was calculated ranging from 0
(death) to 1 (full health) based on the answers of the five
domains using the Dutch EQ-5D-5L value set [16, 17].
The EQ-5D-5L measure also consists of a visual
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analogue scale (VAS) for general health that ranges from
0 (worst imaginable health) to 100 (best imaginable
health) [18].
Itching and pain were separately measured by the
POSAS 2.0 (patient part) [19]. The POSAS consists of
six items: pain, itching, colour, thickness, relief and pli-
ability of a scar [20]. For present study, only the two
items on pain and itching were used. Items were scored
on a 10-point VAS scale ranging from 1 (no pain/itch)
to 10 (extreme pain/itch). Participants were asked to
complete these POSAS items for their – in their opinion
– most severe scar.
Data analyses
IBM SPSS Statistics 23 was used for the analyses. A
sample size calculation was performed. A sample size
of 118 patients was required when alpha was set at 0.05
and a power of 80%. This enables the detection of R2 ≥
0.15 (G-power was used to calculate the sample size
with a given power and effect size). A non-response
analysis was performed to study whether responders
and non-responders differed. Mann Whitney U tests
were used for continuous variables and chi-square tests
for categorical variables. Descriptive statistics were used
to assess characteristics as well as outcomes of the EQ-
5D-5L and the POSAS pain and itching items. Gener-
ally, results were studied overall and for the subgroups:
patients with versus without comorbidity, and the sub-
groups patients with pain and no itching (as reported
on the POSAS) and patients with itching and no pain
(POSAS).
Head-to-head comparisons were used to compare out-
comes of the EQ-5D-5L PD domain and the POSAS
pain and itching items. The proportion of patients with
corresponding answers was assessed and tested using a
chi-squared test. Corresponding answers were defined as
reporting problems on both the EQ-5D-5L PD domain
and a POSAS item, so for example for the EQ-5D-5L
PD domain and POSAS pain, a patient reported corre-
sponding answers as he/she reported problems on both
EQ-5D-5L PD domain (score > 1) and POSAS pain
(score > 1). To assess whether the EQ-5D-5L PD domain
reflects the worst level of both POSAS items, a POSAS
worst count variable was created based on the POSAS
pain and itching items. So, if POSAS pain was scored
higher (worse) than POSAS itching, this score was used
in the worst level variable, or vice versa. The worst out-
come was compared with the EQ-5D-5L PD domain
outcome.
We used the Spearman rank correlation coefficient
to establish convergent validity of the EQ-5D-5L PD
using the POSAS items as reference. Rank order cor-
relation between the EQ-5D-5L PD domain and
POSAS pain and itching items, as well as between all
other EQ-5D-5L domains and POSAS pain and itch-
ing items were studied, both in the total sample as in
the defined subgroups [21]. Both the EQ-5D-5L PD
domain and the POSAS items were treated as numer-
ical variables. Also, the rank order correlation be-
tween the EQ-5D-5L PD domain and the POSAS
worst count variable was assessed, both in the total
sample as in patients that reported both pain and
itching on the POSAS. According to Cohen’s criteria,
strength of the correlations was regarded strong if r ≥
0.50, moderate if r ≥ 0.30–0.49, and weak if r ≥ 0.10–
0.29 [22].
Then, it was assessed to what extent variability in pain
and itching was captured by the EQ-5D-5L PD domain.
The correlation between the POSAS pain and itching
item and the correlation with the EQ-5D-5L PD domain
was studied. For each combination of POSAS pain and
itching outcomes, the mean EQ-5D-5L PD domain score
was calculated. Multivariable regression analyses were
applied to predict EQ-5D-5L PD domain from the
POSAS pain and itching items, with relevant demo-
graphic (age, sex, comorbidity) and clinical variables
(length of hospital stay, %TBSA burned, number of sur-
geries, aetiology) added. Lastly, the EQ-VAS was pre-
dicted by the POSAS pain and itching items, as well as
by the EQ-5D-5L PD. The significance level for all ana-
lyses was set at p < 0.05.
Hypotheses
1. Itching is captured by the EQ-5D-5L PD, which is
tested by the presence of problems on the EQ-5D-
5L PD domain for the subgroup of patients who do
not score problems on POSAS pain, but do score
problems on POSAS itching.
2. The association between the EQ-5D-5L PD domain
scores and the POSAS pain item score is of com-
parable magnitude compared to the association be-
tween the EQ-5D-5L PD domain and the POSAS
itching item score. If both symptoms coincide, the
EQ-5D-5L PD domain reflects the worst level of
both POSAS items.
3. The EQ-5D-5L PD domain score is stronger related
to the POSAS pain item score in patients without
rather than with comorbidity, because patients with
comorbidity have a higher probability to experience
pain due to their comorbid chronic disease.
4. The association between the other EQ-5D-5L do-
mains and the POSAS pain and itching items is
lower compared to that between EQ-5D-5L PD do-
main and the same items.
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5. There is a strong correlation between the EQ-5D-
5L PD domain score and the POSAS pain and itch-
ing item score.
Results
Participants
A total of 517 patients were eligible, of whom 257 were
willing to participate. Two hundred forty-five patients
(47.4%) completed all items of the EQ-5D-5L and
POSAS and were included in this study. Non-response
analysis showed that responders were more often fe-
males (p = 0.03) and were older (p < 0.01) than non-
responders (Additional file 1). Table 1 shows the charac-
teristics of the study population. Participants had a mean
age of 47.4 years (SD 16.8) and 62.0% was male. Median
%TBSA burned was 6.0% (IQR: 2.0–12.5) and mean
length of stay 17.9 days (SD 22.2). Patients with comor-
bidity were significantly older, more often female, had
more severe burns, a longer hospital stay and underwent
more surgeries.
EQ-5D-5L and POSAS outcomes
Mean EQ-5D-5L index value was 0.87 (SD 0.18) and the
mean EQ-VAS was 81.6 (SD 15.7) (Table 1). Most prob-
lems were reported on the PD domain; 39.2% of the par-
ticipants reported at least mild problems. In total, 63
respondents (25.7%) reported pain (POSAS pain score ≥
2) and 118 (48.2%) reported itching (POSAS itching
score ≥ 2). Patients with comorbidity had significantly
worse outcomes on both the EQ-5D-5L as on the
POSAS pain and itching items (Table 1).
Head-to-head comparisons
EQ-5D-5L PD domain and POSAS pain
In total, 27% of the patients (n = 67) reported non-
corresponding answers on the POSAS pain item and
EQ-5D-5L PD domain (Table 2). The majority of re-
spondents with non-corresponding answers (75%, n =
50) reported no pain on the POSAS and slight to severe
problems on the EQ-5D-5L PD domain. Chi square test
showed that answers on both items were related (X2
(1)=40.735; p < 0.001). For patients with comorbidity, the
percentage of respondents with non-corresponding an-
swers was 34%, of which most (81%) reported no pain
on the POSAS and slight to severe problems on the EQ-
5D-5L PD domain. For patients without comorbidity,
the percentage of respondents with non-corresponding
answers was 25%, with 72% of them reporting no pain
on the POSAS and slight to severe problems on the EQ-
5D-5L PD domain. Of the 10 respondents who reported
pain and no itching (POSAS), 70% reported problems on
the EQ-5D-5L PD domain. For respondents with and
without comorbidity, this percentage was 67 and 81%,
respectively.
EQ-5D-5L PD domain and POSAS itching
Non-corresponding answers on the POSAS itching item
and EQ-5D-5L PD domain were given by 30% of the pa-
tients (n = 74) (Table 2), of which 65% (n = 48) reported
itching on the POSAS and no problems on the EQ-5D-
5L PD domain. Chi square test showed that answers on
both items were related (X2 (1)=38.741; p < 0.001). For
patients with comorbidity, the percentage of respondents
with non-corresponding answers was 31%, of which 33%
reported itch on the POSAS and no on the EQ-5D-5L
PD domain. For patients without comorbidity, 29% gave
non-corresponding answers, with 75% of them reporting
itch on the POSAS and no problems on the EQ-5D-5L
PD domain. Of the 65 respondents who reported itching
and no pain (POSAS), 48% reported problems on the
EQ-5D-5L PD domain. For respondents with and with-
out comorbidity, this percentage was 70 and 44%,
respectively.
EQ-5D-5L PD domain and POSAS worst count variable
A total of 70 patients (29%) gave non-corresponding an-
swers on the POSAS worst count variable versus the
EQ-5D-5L PD domain. Most of them (73%) reported
pain and/or itching on the POSAS and no pain/discom-
fort on the EQ-5D-5L PD domain. Comparing patients
reporting no problems, 117 patients (48%) reported no
problems on the combined POSAS variable, whereas
149 patients (61%) reported no problems on the EQ-5D-
5L PD domain.
Convergent validity of the EQ-5D-5L PD domain
EQ-5D-5L PD domain and POSAS pain and itching
Spearman rank correlation coefficients of the EQ-5D-5L
domains and the POSAS pain and itching items are dis-
played in Table 3. The Spearman rank correlation coeffi-
cients of the EQ-5D-5L PD domain with the POSAS
pain and POSAS itching were 0.468 (p < 0.001) and
0.473 (p < 0.001), respectively. In the subgroup of pa-
tients reporting pain but no itching on the POSAS,
Spearman’s rank correlation coefficient was 0.585 (p =
0.076), indicating a strong correlation. In the subgroup
of patients with itching and no pain, the correlation was
0.408 (p = 0.001), indicating a moderate correlation. The
correlation between the EQ-5D-5L PD domain and the
POSAS pain item and between the EQ-5D-5L PD do-
main and the POSAS itching item were comparable in
respondents with and without comorbidity.
EQ-5D-5L PD domain and POSAS worst count variable
In the total sample, the rank correlation between the
EQ-5D-5L PD domain and the combined worst count
POSAS variable was 0.530 (p < 0.001).
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Table 1 Characteristics of study population
Variable Total sample (n = 245) Without comorbidity (n = 183) With comorbidity (n = 62) P-value
Gender: male, n(%) 152 (62.0%) 124 (67.8%) 28 (45.2%) 0.002
Age at follow-up (M, SD) 47.4 (16.8) 38.5 (16.3) 57.2 (14.2) < 0.001
%TBSA (Median, IQR) 6.0 (2.0–12.5) 5.0 (1.5–11.0) 8.0 (3.0–16.5) 0.012
Length of hospital stay (M, SD) 17.9 (22.2) 15.6 (20.8) 24.9 (24.7) < 0.001
Number of surgeries (M, SD) 1.3 (2.0) 1.1 (1.9) 1.8 (2.2) 0.006
Aetiology, n(%) 0.197
Flame 141 (58.0%) 101 (55.5%) 40 (65.6%)
Scald 46 (19.0%) 34 (18.6%) 12 (19.7%)
Other 56 (23.0%) 47 (25.8%) 9 (14.8%)
Time since burn (years) (M, SD) 5.6 (0.5) 5.6 (0.5) 5.6 (0.5) 0.768
Comorbidity, n pre-existing chronic conditions (%)
No 183 (74.7%)
One 44 (18.0%)
More than one 18 (7.3%)
EQ-5D-5L scores
Index value (M, SD) 0.87 (0.18) 0.90 (0.09) 0.77 (0.23) < 0.001
EQ-VAS (M, SD) 81.6 (15.7) 84.1 (14.6) 74.2 (16.5) < 0.001
Mobility (% with problems) 15.5% 9.8% 32.3% < 0.001
Self-care (% with problems) 7.8% 3.8% 19.4% < 0.001
Usual activities (% with problems) 23.3% 16.9% 41.9% 0.001
Pain/discomfort (% with problems) 39.2% 33.3% 56.5% 0.001
Anxiety/depression (% with problems) 31.4% 27.3% 43.5% 0.009
POSAS Patient Scale scores
% patients with pain (POSAS pain score≥ 2) 25.7% 22.4% 35.5% 0.174
% patients with itching (POSAS itching score≥ 2) 48.2% 48.6% 46.8% 0.166
M, SD mean, standard deviation, IQR interquartile range, %TBSA percentage total body surface area, EQ-VAS EQ Visual Analogue Scale
Table 2 Head-to-head comparison of outcomes of the EQ-5D-5L pain/discomfort domain and POSAS pain and itching items
EQ-5D-5L pain/discomfort
Number of patients that reported problems
(n, %)
Number of patients that reported no problems
(n, %)
POSAS pain
Number of patients that reported pain (n, %) 46 (18.8%) 17 (6.9%)
Number of patients that reported no pain (n, %) 50 (20.4%) 132 (53.9%)
POSAS itching
Number of patients that reported itching (n, %) 70 (28.6%) 48 (19.6%)
Number of patients that reported no itching
(n, %)
26 (10.6%) 101 (41.2%)
POSAS worst count variablea
Number of patients that reported pain/itching
(n, %)
77 (31.4%) 51 (20.8%)
Number of patients that reported no pain/itching
(n, %)
19 (7.8%) 98 (40.0%)
Values printed in bold are considered corresponding answers, whereas the values not printed in bolt are considered non-corresponding answers
aa POSAS worst count variable was created based on the POSAS pain and itching items. If POSAS pain was scored higher (worse) than POSAS itching, this score
was used in the worst level variable, or vice versa
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EQ-5D-5L other domains and POSAS pain and itching
The correlation coefficients of the other EQ-5D-5L
domains and the POSAS pain item ranged from 0.099
(p = 0.121) for self-care to 0.359 (p < 0.001) for usual ac-
tivities (Table 3). The correlation coefficients of the
other EQ-5D-5L domains and the POSAS itching item
ranged from 0.058 (p = 0.368) for mobility to 0.301 (p <
0.001) for usual activities.
Variability in pain and itching and the EQ-5D-5L PD domain
Outcomes of the EQ-5D-5L PD domain versus POSAS
pain outcomes are displayed in Fig. 1, and versus POSAS
itching outcomes in Fig. 2. The correlation between the
POSAS pain and itching items and the correlation with
the EQ-5D-5L PD domain is shown in Fig. 3, with the
Spearman rank correlation coefficient between the
POSAS pain and itching items being 0.489 (p < 0.001),
indicating a moderate correlation between both POSAS
items.
Multivariate regression analysis showed that POSAS
pain (unstandardized Beta = 0.14) and POSAS itching
(unstandardized Beta = 0.08) were significantly associated
with the EQ-5D-5L PD domain (both p < 0.001).
In respondents with comorbidity, POSAS pain
(unstandardized Beta = 0.15; p = 0.040), but not POSAS
itching (unstandardized Beta = 0.08; p = 0.155) was
Table 3 Association of all EQ-5D-5L domains (5 level score) with POSAS pain and itching (1–10 score) in terms of Spearman’s rank
correlation
Other EQ-5D-5L domains
Pain/ discomfort Mobility Self-care Usual activities Anxiety/ depression
All (n = 245)
POSAS pain 0.468* 0.153* 0.099 0.359* 0.174*
POSAS itch 0.473* 0.058 0.096 0.301* 0.192*
Subgroup POSAS pain, no itching (n = 10)
POSAS pain 0.585 0.041 NA 0.208 0.609
Subgroup POSAS itching, no pain (n = 65)
POSAS itch 0.408* 0.030 0.235 0.303* 0.256*
Subgroup with comorbidity (n = 62)
POSAS pain 0.453* 0.019 0.106 0.272* 0.206
POSAS itch 0.472* −0.025 0.141 0.235 0.243
Subgroup without comorbidity (n = 183)
POSAS pain 0.451* 0.196* 0.047 0.374* 0.131
POSAS itch 0.481* 0.095 0.047 0.336* 0.174*
*p < 0.05 for the correlation, based on Spearman’s correlation coefficient
Fig. 1 Outcomes of the EQ-5D-5L pain/discomfort domain versus POSAS pain outcomes. POSAS pain was scored on a 10-point scale ranging
from 1 (no pain) to 10 (extreme pain)
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significantly associated with the EQ-5D-5L PD domain. In
respondents without comorbidity, however, both POSAS
items pain (unstandardized Beta = 0.14; p < 0.001) and
itching (unstandardized Beta = 0.09; p < 0.001) were sig-
nificantly associated with the EQ-5D-5L PD domain.
Prediction of the EQ-VAS was also studied using multi-
variate regression analysis. POSAS pain (unstandardized
Beta = 0.61) and POSAS itching (unstandardized Beta = −
0.16) were not significantly associated (p > 0.05) with the
EQ-VAS, whereas the EQ-5D-5L PD domain was found
to be associated (unstandardized Beta = − 7.94; p < 0.001)
(Additional file 2). Also, age and having comorbidity were
found to be significant predictive factors for the EQ-VAS
(Additional file 2). In the subgroups of patients with and
Fig. 2 Outcomes of the EQ-5D-5L pain/discomfort domain versus POSAS itching outcomes. POSAS itching was scored on a 10-point scale
ranging from 1 (no itching) to 10 (extreme itching)
Fig. 3 Mean EQ-5D-5L pain/discomfort (PD) domain scores for combinations of POSAS pain and itching outcomes that appear ≥2 times.The
colored dots represent this mean EQ-5D-5L PD domain score, with dark green: mean EQ-5D-5L PD domain score = 1 - < 2; green: mean EQ-5D-5L
PD domain score = 2 - < 3; orange: mean EQ-5D-5L PD domain score = 3 - < 4; red: mean EQ-5D-5L PD domain score = 4–5. *21 patients had a
POSAS pain score of 1 (x-axis) and POSAS itching score of 2 (y-axis) and the mean EQ-5D-5L pain/discomfort domain score of these patients was
1.3 (shown as dark green spot).** 3 patients had a POSAS pain score of 6 (x-axis) and POSAS itching score of 6 (y-axis) and the mean EQ-5D-5L
pain/discomfort domain score of these patients was 3.0 (shown as yellow spot)
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without comorbidity, similar results were found with only
the EQ-5D-5L PD domain being significantly associated
with the EQ-VAS.
Discussion
This study investigated the sensitivity of the EQ-5D-5L
PD domain for pain and itching in a sample of burn pa-
tients. Overall, most patients gave corresponding an-
swers on the EQ-5D-5L PD domain and on the POSAS
pain and itching item, but details were different. Overall,
more patients reported problems when assessed by the
POSAS compared to the EQ-5D-5L PD domain. Both
POSAS pain and EQ-5D-5L PD domain, and POSAS
itching and EQ-5D-5L PD domain were shown to be
moderately correlated, with similar associations in pa-
tients with and without comorbidity. EQ-5D-5L usual
activities, anxiety/depression and mobility were to a
lesser extent correlated to the POSAS pain and/or itch-
ing item. A strong correlation between EQ-5D-5L PD
domain and POSAS pain in patients with pain was
found, a moderate correlation between EQ-5D-5L PD
domain and POSAS itching in patients reporting itching
was found. Scale congruence is present between the EQ-
5D-5L PD domain score and the POSAS pain and itch-
ing item score.
Our results, which indicate that more problems are re-
ported by the use of a single item question compared to
a composite measure, are in line with an earlier study.
The study by Tsuchiya et al. examined splitting of the
composite EQ-5D-5L PD dimension into separate items
and found that problems were more frequently reported
by the separate items (49% of sample reporting prob-
lems) compared to the composite dimension (43% of
sample reporting problems), however, this difference
was not statistically significant [23]. Interestingly, this
difference was larger and statistically significant for the
anxiety/depression dimension in the same study. The
proportion of patients that reported problems for the
separate items (55%) was substantially larger than for
the composite anxiety/depression dimension (43%). The
authors suggested that the PD dimension is interpreted
more literally (read as pain or discomfort) compared to
the anxiety/depression dimension (possibly read as anx-
iety and depression) [23].
Our results confirm our first hypothesis that the cor-
relation between the EQ-5D-5L PD domain and the
POSAS pain item is comparable to the correlation be-
tween the EQ-5D-5L PD domain and the POSAS itching
item. Only a small percentage of patients reported non-
corresponding answers, e.g. no problems on the EQ-5D-
5L PD domain (score = 1), and problems on the POSAS
pain (score > 1). Part of this inconsistency may be the
consequence of differential instruction: the POSAS was
completed for the patients –in their opinion– worst scar.
The EQ-5D-5L PD domain on the other hand, reflects
the patient’s overall condition. Most patients (75%) that
reported inconsistently outcomes, reported pain in the
EQ-5D-5L PD domain and yet no pain on the POSAS
pain item. A possible explanation for this finding may be
that pain outside the scar may have a relation to a pre-
existing condition (comorbidity). However, the correlation
between the EQ-5D-5L PD domain and the POSAS pain
item was higher rather than lower in the group patients
without comorbidity than in the group with comorbidity.
For itching, a different pattern was observed; most pa-
tients with inconsistent answers reported itching on the
POSAS itching item, but no PD in the EQ-5D PD domain.
Potentially because these patients did not consider itching
as discomfort, because of fluctuations of itching levels, or
because they simply overlook the discomfort addition.
Subgroup analysis, in patients with respectively pain
and itching, showed that EQ-5D-5L PD domain and
POSAS pain had a good correlation, whereas the EQ-
5D-5L PD domain and POSAS itching showed a moder-
ate correlation. Pain seems thus to be sufficiently
covered by the EQ-5D-5L PD; however, results on itch-
ing are less conclusive in our sample of burn patients.
An earlier study in psoriasis patients identified ‘skin irri-
tation, including itching’ as a separate candidate domain.
Psychometric analyses showed that the new domain cap-
tured additional variance over the existing five EQ-5D-
5L domains [5]. Additional analyses on both the ex-
planatory and discriminatory power of an additional
itching domain are valuable to conclude whether an
extra domain captures additional information.
This study has strengths and limitations. A strength
was the unselected cohort nature, and the high preva-
lence of pain and itching which allowed us to study
whether itching and pain are captured by the EQ-5D-5L
PD domain, including interaction effects. Another
strength was that both instruments were validated in the
burn population [20, 24]. A limitation was the relatively
low variability in pain and itching reported by the pa-
tients, only few patients reported severe pain and/or
itching, potentially due to the long-term follow-up data
that we used - this limits scale correspondence to be
scrutinized. Another apparent limitation was the differ-
ence in instruction (timeframe, body part to focus on).
The EQ-5D-5L refers to your health today, whereas the
POSAS asks about the past weeks. By using a different
timeframe, answers might be slightly different on the
two instruments. Also, burn scars can cause other prob-
lems that are measured by the POSAS instrument, in-
cluding pliability and thickness of a scar. These items
might also be detected by the EQ-5D-5L PD domain.
This was, however, beyond the scope of present study to
investigate this, but it might be an interesting topic for
future research.
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Conclusions
Our findings indicate that, in a sample of burn patients,
pain and itching are captured by the broader EQ-5D-5L
PD domain. The EQ-5D-5L PD domain can thus be
used to assess pain and itching in relation to HRQL, but
the POSAS pain and itching items are more sensitive.
The EQ-5D-5L is, however, no replacement of the
POSAS when the POSAS is used for its primary aim; as-
sessment of scar quality.
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